HK1129388A1 - Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use - Google Patents

Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use

Info

Publication number
HK1129388A1
HK1129388A1 HK09108321.4A HK09108321A HK1129388A1 HK 1129388 A1 HK1129388 A1 HK 1129388A1 HK 09108321 A HK09108321 A HK 09108321A HK 1129388 A1 HK1129388 A1 HK 1129388A1
Authority
HK
Hong Kong
Prior art keywords
human protein
pharmaceutical use
tyrosine phosphatase
phosphatase inhibitors
inhibitors
Prior art date
Application number
HK09108321.4A
Other languages
English (en)
Chinese (zh)
Inventor
Jeffrey Lyle Gray
Cynthia Monesa Clark
Kande Amarasinghe
Mathew Brian Maier
Ryan Nichols
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38704718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1129388(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of HK1129388A1 publication Critical patent/HK1129388A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09108321.4A 2006-06-27 2009-09-10 Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use HK1129388A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81682506P 2006-06-27 2006-06-27
PCT/US2007/014824 WO2008002571A2 (en) 2006-06-27 2007-06-27 Human protein tyrosine phosphatase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
HK1129388A1 true HK1129388A1 (en) 2009-11-27

Family

ID=38704718

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09108321.4A HK1129388A1 (en) 2006-06-27 2009-09-10 Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use
HK15104703.3A HK1203960A1 (en) 2006-06-27 2015-05-18 Human protein tyrosine phosphatase inhibitors and their pharmaceutical use

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15104703.3A HK1203960A1 (en) 2006-06-27 2015-05-18 Human protein tyrosine phosphatase inhibitors and their pharmaceutical use

Country Status (23)

Country Link
US (3) US7589212B2 (xx)
EP (3) EP3287455A1 (xx)
JP (1) JP5201740B2 (xx)
KR (1) KR101157844B1 (xx)
CN (1) CN101506204B (xx)
AU (1) AU2007265455B2 (xx)
BR (1) BRPI0713349A2 (xx)
CA (1) CA2656915C (xx)
CO (1) CO6150143A2 (xx)
CY (1) CY1115588T1 (xx)
DK (2) DK2041129T3 (xx)
ES (2) ES2660571T3 (xx)
HK (2) HK1129388A1 (xx)
IL (1) IL196130A (xx)
MX (1) MX2009000290A (xx)
NZ (1) NZ574405A (xx)
PL (2) PL2041129T3 (xx)
PT (2) PT2803663T (xx)
RU (1) RU2430101C2 (xx)
SI (1) SI2041129T1 (xx)
TR (1) TR201802280T4 (xx)
WO (1) WO2008002571A2 (xx)
ZA (1) ZA200900558B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
RU2014146121A (ru) * 2009-01-12 2015-06-10 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2726946T3 (es) * 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
KR101483831B1 (ko) 2009-11-06 2015-01-21 에르피오 세러퓨틱스 인코포레이티드 대장염 치료용 조성물 및 방법
JP2013539756A (ja) * 2010-10-07 2013-10-28 アエルピオ セラピューティックス インコーポレイテッド 眼球浮腫、血管新生および関連疾患を処置するための組成物および方法
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
EP3501536A1 (en) 2011-10-13 2019-06-26 Aerpio Therapeutics, Inc. Treatment of ocular disease
RU2507597C2 (ru) * 2012-05-23 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы никорандилом
ES2766326T3 (es) 2013-03-15 2020-06-12 Aerpio Therapeutics Inc Composiciones, formulaciones y métodos para tratar enfermedades oculares
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
RU2526466C1 (ru) * 2013-04-04 2014-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Средство для стимуляции васкуляризации сердечной мышцы при постинфарктном ее ремоделировании в эксперименте
WO2015126860A1 (en) 2014-02-19 2015-08-27 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
JP6959924B2 (ja) 2015-09-23 2021-11-05 エアーピオ ファーマシューティカルズ， インコーポレイテッド Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
US10900319B2 (en) 2017-12-14 2021-01-26 Exacta-Frac Energy Services, Inc. Cased bore straddle packer
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
JP2022530657A (ja) 2019-04-29 2022-06-30 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
GB2589400A (en) 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof
US11613534B2 (en) 2019-10-29 2023-03-28 EyePoint Pharmaceuticals, Inc. Small molecule activators of Tie-2
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69332197T2 (de) * 1992-03-13 2003-04-17 Organon Teknika Bv Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
WO1993023075A1 (en) * 1992-05-14 1993-11-25 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
DK0833934T4 (da) * 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
JPH106346A (ja) * 1996-06-19 1998-01-13 Takemoto Oil & Fat Co Ltd プラスチック成形型の製造方法及びプラスチック成形型
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
AU5062500A (en) 1999-04-26 2000-11-10 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
AU5147700A (en) * 1999-05-19 2000-12-05 Amgen, Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
AU775625B2 (en) 1999-08-27 2004-08-05 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6589758B1 (en) * 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
EP1409540A2 (en) 2000-09-27 2004-04-21 The Procter & Gamble Company Melanocortin receptor ligands
WO2003082263A1 (en) * 2002-03-29 2003-10-09 Ontogen Corporation Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20050154011A1 (en) * 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
WO2005027183A2 (en) * 2003-09-17 2005-03-24 Koninklijke Philips Electronics N.V. High intensity discharge lamp
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas

Also Published As

Publication number Publication date
US20070299116A1 (en) 2007-12-27
CO6150143A2 (es) 2010-04-20
BRPI0713349A2 (pt) 2012-03-06
ES2510674T3 (es) 2014-10-21
JP2009542660A (ja) 2009-12-03
WO2008002571A2 (en) 2008-01-03
IL196130A0 (en) 2009-09-22
KR101157844B1 (ko) 2012-06-22
RU2430101C2 (ru) 2011-09-27
CY1115588T1 (el) 2017-01-04
CA2656915C (en) 2012-08-07
NZ574405A (en) 2012-01-12
AU2007265455A1 (en) 2008-01-03
JP5201740B2 (ja) 2013-06-05
EP2041129A2 (en) 2009-04-01
MX2009000290A (es) 2009-03-16
AU2007265455A2 (en) 2009-05-21
ES2660571T3 (es) 2018-03-23
PT2803663T (pt) 2018-02-28
KR20090024296A (ko) 2009-03-06
US7589212B2 (en) 2009-09-15
ZA200900558B (en) 2012-04-24
CN101506204A (zh) 2009-08-12
SI2041129T1 (sl) 2014-11-28
EP3287455A1 (en) 2018-02-28
PL2041129T3 (pl) 2014-11-28
WO2008002571B1 (en) 2008-04-17
CA2656915A1 (en) 2008-01-03
WO2008002571A3 (en) 2008-02-14
PT2041129E (pt) 2014-10-08
CN101506204B (zh) 2012-05-30
RU2009102537A (ru) 2010-08-10
DK2803663T3 (en) 2018-03-05
US20120077853A1 (en) 2012-03-29
US20090227639A1 (en) 2009-09-10
US8338615B2 (en) 2012-12-25
EP2803663B1 (en) 2017-11-29
PL2803663T3 (pl) 2018-05-30
EP2041129B1 (en) 2014-09-03
IL196130A (en) 2014-04-30
US8188125B2 (en) 2012-05-29
TR201802280T4 (tr) 2018-03-21
AU2007265455B2 (en) 2011-11-10
EP2803663A1 (en) 2014-11-19
DK2041129T3 (da) 2014-10-13
HK1203960A1 (en) 2015-11-06

Similar Documents

Publication Publication Date Title
SI2041129T1 (sl) Inhibitorji človeške protein-tirozin-fosfataze in njihova farmacevtska uporaba
SI2038265T1 (sl) Inhibitorji človeške protein-tirozin-fosfataze in postopki uporabe
PL2592072T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie
GB0625659D0 (en) Therapeutic compounds and their use
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
ZA200902084B (en) Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
EP2046413A4 (en) MEDICAL SYSTEMS AND APPLICATION METHOD
HK1136160A1 (en) Disintegrin variants and pharmaceutical uses thereof
IL198893A0 (en) Lipase variants for pharmaceutical use
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
IL204442A (en) Inhibitors of atpase-0fif, medicinal preparations containing them and their use
PL2036882T3 (pl) Związki o jonach obojnaczych i ich zastosowanie
IL194751A0 (en) Drugs and uses
EP2224928A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
GB2443336B (en) Spiruchostatin analogues and their medicinal use
HK1141211A1 (en) Novel seh inhibitors and their use
GB0516069D0 (en) Pharmaceutical and use thereof
EP2217068A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
EP2209376A4 (en) NEW SEH-HEMMER AND ITS USE
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0614365D0 (en) Pharmaceutical compositions and their use
EP2097378A4 (en) NOVEL INHIBITORS OF SEH AND USE THEREOF
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0625633D0 (en) Therapeutic compounds and their use
HU0600403D0 (en) New pharmaceutical intermediates and their use

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT/PROPRIETOR FROM AERPIO THERAPEUTICS INC. TO AERPIO THERAPEUTICS, INC.

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230625